JP2020502202A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502202A5
JP2020502202A5 JP2019533344A JP2019533344A JP2020502202A5 JP 2020502202 A5 JP2020502202 A5 JP 2020502202A5 JP 2019533344 A JP2019533344 A JP 2019533344A JP 2019533344 A JP2019533344 A JP 2019533344A JP 2020502202 A5 JP2020502202 A5 JP 2020502202A5
Authority
JP
Japan
Prior art keywords
composition
kcal
mmol
hydroxybutyrate
pack
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019533344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502202A (ja
JP7174428B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/081394 external-priority patent/WO2018114309A1/en
Publication of JP2020502202A publication Critical patent/JP2020502202A/ja
Publication of JP2020502202A5 publication Critical patent/JP2020502202A5/ja
Application granted granted Critical
Publication of JP7174428B2 publication Critical patent/JP7174428B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019533344A 2016-12-23 2017-12-04 救命救急処置の処置における使用のための３－ヒドロキシブチレートの単独または併用 Active JP7174428B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438771P 2016-12-23 2016-12-23
US62/438,771 2016-12-23
LU100353 2017-08-01
LU100353 2017-08-01
PCT/EP2017/081394 WO2018114309A1 (en) 2016-12-23 2017-12-04 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment

Publications (3)

Publication Number Publication Date
JP2020502202A JP2020502202A (ja) 2020-01-23
JP2020502202A5 true JP2020502202A5 (enExample) 2021-01-21
JP7174428B2 JP7174428B2 (ja) 2022-11-17

Family

ID=60582587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533344A Active JP7174428B2 (ja) 2016-12-23 2017-12-04 救命救急処置の処置における使用のための３－ヒドロキシブチレートの単独または併用

Country Status (10)

Country Link
US (2) US20190314307A1 (enExample)
EP (1) EP3558291A1 (enExample)
JP (1) JP7174428B2 (enExample)
KR (1) KR20190099469A (enExample)
CN (1) CN110248652B (enExample)
AU (1) AU2017381059B2 (enExample)
BR (1) BR112019012899A2 (enExample)
CA (1) CA3047362A1 (enExample)
CO (1) CO2019007531A2 (enExample)
MX (1) MX390420B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11666548B2 (en) 2020-06-05 2023-06-06 Baxter International Inc. Parenteral nutrition formulation
US20240269096A1 (en) * 2022-12-31 2024-08-15 American Ketone Therapeutics LLC Rapid Onset Therapeutic Ketosis Enabled by D-BetaHydroxyButyric Acid Systems, Compounds and Methods for Sepsis Protection and Enhanced Medical Recovery
CN117243939B (zh) * 2023-11-14 2025-03-07 南京今冉生物新材料科技有限公司 一种酮体缓释物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338090C (en) * 1998-07-22 2009-07-14 Metabolix, Inc. Nutritional and therapeutic compositions of 3-hydroxyacids for increasing blood ketone bodies
CA2339941A1 (en) * 1998-09-15 2000-03-23 Btg International Limited Use of cyclic esters of r-3-hydroxybutyrate for treatment of metabolic and neural degenerative disorders
DK1648952T3 (en) * 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
CN100344280C (zh) * 2005-08-01 2007-10-24 清华大学 3－羟基丁酸及其衍生物的新用途
ES2655367T3 (es) * 2008-08-21 2018-02-19 Oxford University Innovation Limited Bebida que comprende éster de hidroxibutirato y uso médico de la misma
GB201206192D0 (en) 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown

Similar Documents

Publication Publication Date Title
FI3426285T3 (fi) Pegyloidun urikaasin formulaatioita ja annoksia
JP2020534268A5 (enExample)
JP2015503590A5 (enExample)
JP2019507797A5 (enExample)
JP2019048843A5 (enExample)
NZ727849A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
FI3448426T3 (fi) Menetelmiä familiaalista hyperkolesterolemiaa sairastavien potilaiden hoitoon
JP2014077003A5 (enExample)
RU2015127794A (ru) Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
JP2012530779A5 (enExample)
JP2019533715A5 (enExample)
US20230321022A1 (en) Reversibly protected thiolated electrophilic fatty acids as prodrugs
FI4349369T3 (fi) Lääkkeen biologisen hyötyosuuden lisääminen naltreksonihoidossa
CN104667283B (zh) 一种治疗血脂异常和动脉粥样硬化的复方药物组合
Pflieger et al. Medical management of stable coronary artery disease
DiNicolantonio et al. Ezetimibe plus moderate-dose simvastatin after acute coronary syndrome: what are we IMPROVEing on?
CN103239439B (zh) 用于治疗高血脂及动脉粥样硬化的组合物及其用途
Gryn et al. New oral agents for treating dyslipidemia
Filippatos et al. Are Lower Levels of LDL-Cholesterol Really Better? Looking at the Results of IMPROVE-IT: Οpinions of Τhree Experts–III
IL291570B2 (en) Pharmaceutical preparations
Kitayama Role of regional anesthesia in the enhanced recovery after surgery program
Stafford Hypersensitivity Reaction to Amiodarone in a Patient with a Previous Reaction to an lodinated Radiocontrast Agent
Suh et al. Statin intolerance: An overview of the current status and possible treatment options
KR20180093604A (ko) 라니티딘염산염 및 트리메부틴말레산염을 포함하는 약제학적 복합제제
NZ755274A (en) 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment